{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:49:48Z","timestamp":1785415788727,"version":"3.56.0"},"reference-count":44,"publisher":"American Association for Cancer Research (AACR)","issue":"1","funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA279968"],"award-info":[{"award-number":["R01CA279968"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM152449"],"award-info":[{"award-number":["R35GM152449"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA233975"],"award-info":[{"award-number":["R01CA233975"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA257655"],"award-info":[{"award-number":["R01CA257655"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["K12GM000678"],"award-info":[{"award-number":["K12GM000678"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K08CA267307"],"award-info":[{"award-number":["K08CA267307"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32GM007753"],"award-info":[{"award-number":["T32GM007753"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32GM144273"],"award-info":[{"award-number":["T32GM144273"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["F30CA260780"],"award-info":[{"award-number":["F30CA260780"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006352","name":"Virginia and D.K. Ludwig Fund for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019371","name":"Bakewell Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019371","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014549","name":"Stanford Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014549","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","award":["DR-CI#71-14"],"award-info":[{"award-number":["DR-CI#71-14"]}],"id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Chimeric antigen receptor (CAR) T cells produce durable remissions in some patients with large B-cell lymphoma, but outcomes are poor in patients with large tumor burdens or limited CAR T-cell expansion. To understand these relationships and explore potential interventions, we applied established population pharmacokinetic\/pharmacodynamic principles to model kinetics of axicabtagene ciloleucel (axi-cel) concentrations and tumor responses to axi-cel, and validated model outputs using independent cohorts. This mechanistic model reproduces and explains poor outcomes associated with high tumor burden and low CAR T-cell expansion, finding that proliferation of large lymphoma populations can outpace the cytotoxic effect of CAR T cells. A high ratio of lymphoma cells to CAR T cells is effectively a mechanism of CAR T-cell resistance, which could be modified by tumor debulking before infusion. This model predicts that reducing tumor burden before CAR T-cell infusion may improve durable remission rate. Future clinical studies optimizing bridging therapy may therefore enhance the success of CAR T-cell therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>A population pharmacokinetic\/pharmacodynamic model of axi-cel in large B-cell lymphoma explains the observation that high tumor burden and low CAR T-cell expansion predict poor outcomes. This model suggests tumor debulking before CAR T infusion or deploying CAR T therapy in measurable residual disease\u2013positive patients after first-line treatment could improve CAR T success rates.<\/jats:p>\n                    <jats:p>See related commentary by Altrock, p. 11<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-25-0138","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:17:01Z","timestamp":1761567421000},"page":"41-50","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Pharmacologic Model Predicts that Tumor Debulking Improves CAR T-cell Efficacy in Large B-cell Lymphoma"],"prefix":"10.1158","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9217-3539","authenticated-orcid":false,"given":"Amy E.","family":"Pomeroy","sequence":"first","affiliation":[{"name":"1Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina."},{"name":"2Computational Medicine Program, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina."},{"name":"3UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5902-5507","authenticated-orcid":false,"given":"Brian J.","family":"Sworder","sequence":"additional","affiliation":[{"name":"4Division of Oncology, Department of Medicine, Stanford University, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4218-1693","authenticated-orcid":false,"given":"Deborah","family":"Plana","sequence":"additional","affiliation":[{"name":"5Laboratory of Systems Pharmacology and the Department of Systems Biology, Harvard Medical School, Boston, Massachusetts."},{"name":"6Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3974-9073","authenticated-orcid":false,"given":"Yanguang","family":"Cao","sequence":"additional","affiliation":[{"name":"3UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina."},{"name":"7Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5153-5625","authenticated-orcid":false,"given":"Ash A.","family":"Alizadeh","sequence":"additional","affiliation":[{"name":"4Division of Oncology, Department of Medicine, Stanford University, Stanford, California."},{"name":"8Stanford Cancer Institute, Institute for Stem Cell Biology & Regenerative Medicine, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5028-7028","authenticated-orcid":false,"given":"Adam C.","family":"Palmer","sequence":"additional","affiliation":[{"name":"1Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina."},{"name":"2Computational Medicine Program, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina."},{"name":"3UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"2026011203071800900_bib1","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMe2118899","article-title":"CAR T-cell therapy for large B-cell lymphoma - Who, when, and how?","volume":"386","author":"Roschewski","year":"2022","journal-title":"N Engl J Med"},{"key":"2026011203071800900_bib2","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"2026011203071800900_bib3","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ccell.2022.12.005","article-title":"Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas","volume":"41","author":"Sworder","year":"2023","journal-title":"Cancer Cell"},{"key":"2026011203071800900_bib4","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","article-title":"Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma","volume":"4","author":"Pinnix","year":"2020","journal-title":"Blood Adv"},{"key":"2026011203071800900_bib5","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","article-title":"Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma","volume":"7","author":"Roddie","year":"2023","journal-title":"Blood Adv"},{"key":"2026011203071800900_bib6","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.1158\/1078-0432.CCR-24-0830","article-title":"Metabolic tumor volume response after bridging therapy determines chimeric antigen receptor T-cell outcomes in large B-cell lymphoma","volume":"30","author":"Hubbeling","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026011203071800900_bib7","doi-asserted-by":"crossref","first-page":"114421","DOI":"10.1016\/j.addr.2022.114421","article-title":"Cellular kinetics: a clinical and computational review of CAR-T cell pharmacology","volume":"188","author":"Qi","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"2026011203071800900_bib8","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.3390\/cancers13122941","article-title":"CARTmath-A mathematical model of CAR-T immunotherapy in preclinical studies of hematological cancers","volume":"13","author":"Barros","year":"2021","journal-title":"Cancers"},{"key":"2026011203071800900_bib9","doi-asserted-by":"crossref","first-page":"1358478","DOI":"10.3389\/fimmu.2024.1358478","article-title":"Designing combination therapies for cancer treatment: application of a mathematical framework combining CAR T-cell immunotherapy and targeted radionuclide therapy","volume":"15","author":"Adhikarla","year":"2024","journal-title":"Front Immunol"},{"key":"2026011203071800900_bib10","doi-asserted-by":"crossref","first-page":"e005360","DOI":"10.1136\/jitc-2022-005360","article-title":"Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse","volume":"10","author":"Liu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026011203071800900_bib11","doi-asserted-by":"crossref","first-page":"20190734","DOI":"10.1098\/rsif.2019.0734","article-title":"Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data","volume":"17","author":"Sahoo","year":"2020","journal-title":"J R Soc Interf"},{"key":"2026011203071800900_bib12","first-page":"20210229","article-title":"The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapy","volume":"288","author":"Kimmel","year":"2021","journal-title":"Proc Biol Sci"},{"key":"2026011203071800900_bib13","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/s41587-023-01687-x","article-title":"Deconvolution of clinical variance in CAR-T cell pharmacology and response","volume":"41","author":"Kirouac","year":"2023","journal-title":"Nat Biotechnol"},{"key":"2026011203071800900_bib14","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.3390\/cancers13112782","article-title":"Early survival prediction framework in CD19-specific CAR-T cell immunotherapy using a quantitative systems pharmacology model","volume":"13","author":"Mueller-Schoell","year":"2021","journal-title":"Cancers"},{"key":"2026011203071800900_bib15","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"key":"2026011203071800900_bib16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/psp4.12388","article-title":"Tisagenlecleucel model-based cellular kinetic analysis of chimeric antigen receptor-T cells","volume":"8","author":"Stein","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2026011203071800900_bib17","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026011203071800900_bib18","unstructured":"U.S. Food and Drug Administration\n          . Clinical pharmacology BLA review of YESCARTA for treatment of adult patients with relapsed or refractory large B-cell lymphoma within 12 months of first line chemoimmunotherapy[Internet]. [Cited 2025 Sep]. Available from: www.fda.gov\/media\/157676\/download."},{"key":"2026011203071800900_bib19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-024-01065-z","article-title":"Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients","volume":"14","author":"Mart\u00edn-Mart\u00edn","year":"2024","journal-title":"Blood Cancer J"},{"key":"2026011203071800900_bib20","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","article-title":"Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R","volume":"90","author":"Comets","year":"2008","journal-title":"Comput Methods Programs Biomed"},{"key":"2026011203071800900_bib21","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1200\/JCO.21.00377","article-title":"Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial","volume":"39","author":"Frank","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026011203071800900_bib22","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ccell.2021.06.012","article-title":"The role of exhaustion in CAR T cell therapy","volume":"39","author":"Delgoffe","year":"2021","journal-title":"Cancer Cell"},{"key":"2026011203071800900_bib23","unstructured":"U.S. Food and Drug Administration\n          . Clinical review: polatuzumab vedotin-piiq (Polivy), BLA 761121 [Internet]. [Cited 2025 Sep. 17]. Available from:www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/761121Orig1s000MedR.pdf."},{"key":"2026011203071800900_bib24","first-page":"JCO2201725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","author":"Thieblemont","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026011203071800900_bib25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/curroncol32030173","article-title":"Enhancing CAR-T efficacy in large B-cell lymphoma with radiation bridging therapy: a real-world single-center experience","volume":"32","author":"Laverdure","year":"2025","journal-title":"Curr Oncol"},{"key":"2026011203071800900_bib26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"2026011203071800900_bib27","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"2026011203071800900_bib28","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026011203071800900_bib29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/hon.3163_112","article-title":"MRD-negativity after frontline DLBCL therapy: pooled analysis of 6 clinical trials","volume":"41","author":"Roschewski","year":"2023","journal-title":"Hematological Oncol"},{"key":"2026011203071800900_bib30","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1001\/jamaoncol.2024.6144","article-title":"Circulating tumor DNA as measurable residual disease in aggressive B-cell lymphoma: a narrative review","volume":"11","author":"Roschewski","year":"2025","journal-title":"JAMA Oncol"},{"key":"2026011203071800900_bib31","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood.2022016747","article-title":"Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma","volume":"140","author":"Thiruvengadam","year":"2022","journal-title":"Blood"},{"key":"2026011203071800900_bib32","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1016\/j.ijrobp.2022.07.596","article-title":"Patterns of relapse and risk reduction following tumor debulking by bridging radiotherapy prior to chimeric antigen receptor T cell therapy in non-hodgkin lymphoma","volume":"114","author":"Hubbeling","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026011203071800900_bib33","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat Med"},{"key":"2026011203071800900_bib34","doi-asserted-by":"crossref","first-page":"e3278692","DOI":"10.1097\/01.HS9.0000975996.32786.92","article-title":"ZUMA-23: a global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma","volume":"7","author":"Westin","year":"2023","journal-title":"Hemasphere"},{"key":"2026011203071800900_bib35","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1182\/blood-2024-194909","article-title":"ALPHA3, a pivotal phase 2 study of first-line consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in patients with large B-cell lymphoma and minimal residual disease after response to standard therapy","volume":"144","author":"Westin","year":"2024","journal-title":"Blood"},{"key":"2026011203071800900_bib36","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2006","journal-title":"Blood"},{"key":"2026011203071800900_bib37","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjh.13463","article-title":"Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis","volume":"170","author":"Howlett","year":"2015","journal-title":"Br J Haematol"},{"key":"2026011203071800900_bib38","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/s41375-025-02582-x","article-title":"Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy","volume":"39","author":"Iacoboni","year":"2025","journal-title":"Leukemia"},{"key":"2026011203071800900_bib39","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1038\/s41375-021-01196-3","article-title":"Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult Acute lymphoblastic leukemia","volume":"35","author":"Perica","year":"2021","journal-title":"Leukemia"},{"key":"2026011203071800900_bib40","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cpt.2040","article-title":"Model-based cellular kinetic analysis of chimeric antigen receptor-T cells in humans","volume":"109","author":"Liu","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"2026011203071800900_bib41","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.3324\/haematol.2022.281954","article-title":"Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response","volume":"108","author":"Jallouk","year":"2023","journal-title":"Haematologica"},{"key":"2026011203071800900_bib42","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamaoncol.2024.1113","article-title":"Comprehensive bridging radiotherapy for limited pre-CART non-hodgkin lymphoma","volume":"10","author":"Saifi","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026011203071800900_bib43","doi-asserted-by":"crossref","first-page":"107","DOI":"10.7326\/0003-4819-89-1-107","article-title":"Growth rate patterns of solid tumors and their relation to responsiveness to therapy: an analytical review","volume":"89","author":"Shackney","year":"1978","journal-title":"Ann Intern Med"},{"key":"2026011203071800900_bib44","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0138\/3665448\/bcd-25-0138.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0138\/3715482\/bcd-25-0138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/1\/41\/3723341\/bcd-25-0138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/1\/41\/3723341\/bcd-25-0138.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:07:29Z","timestamp":1768205249000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/7\/1\/41\/771359\/A-Pharmacologic-Model-Predicts-that-Tumor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,10,27]]},"published-print":{"date-parts":[[2026,1,12]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-25-0138","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.8239515","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.31047093","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31047105","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31047090","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31047099","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31047096","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31047084","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31047087","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]}}}